PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34453221-0	2021	Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.	lenvatinib	0-10	CD274 molecule	Homo sapiens	131-136	
34453221-1	2021	PURPOSE: The aim of this retrospective study was to compare the clinical outcomes of pembrolizumab-lenvatinib-transarterial chemoembolization (TACE) versus lenvatinib-TACE sequential therapy in selected populations of Chinese patients with initially unresectable hepatocellular carcinoma (uHCC) harbouring programmed cell death ligand-1 (PD-L1) expression.	lenvatinib	99-109	CD274 molecule	Homo sapiens	306-336	
34453221-1	2021	PURPOSE: The aim of this retrospective study was to compare the clinical outcomes of pembrolizumab-lenvatinib-transarterial chemoembolization (TACE) versus lenvatinib-TACE sequential therapy in selected populations of Chinese patients with initially unresectable hepatocellular carcinoma (uHCC) harbouring programmed cell death ligand-1 (PD-L1) expression.	lenvatinib	99-109	CD274 molecule	Homo sapiens	338-343	
34453221-1	2021	PURPOSE: The aim of this retrospective study was to compare the clinical outcomes of pembrolizumab-lenvatinib-transarterial chemoembolization (TACE) versus lenvatinib-TACE sequential therapy in selected populations of Chinese patients with initially unresectable hepatocellular carcinoma (uHCC) harbouring programmed cell death ligand-1 (PD-L1) expression.	lenvatinib	156-166	CD274 molecule	Homo sapiens	306-336	
34453221-1	2021	PURPOSE: The aim of this retrospective study was to compare the clinical outcomes of pembrolizumab-lenvatinib-transarterial chemoembolization (TACE) versus lenvatinib-TACE sequential therapy in selected populations of Chinese patients with initially unresectable hepatocellular carcinoma (uHCC) harbouring programmed cell death ligand-1 (PD-L1) expression.	lenvatinib	156-166	CD274 molecule	Homo sapiens	338-343	
34036623-3	2021	APPROACH & RESULTS: First, in patients with HCC, lenvatinib-treated recurrent tumors had lower programmed death ligand 1 (PD-L1) expression and regulatory T cell (Treg) infiltration compared with matched primary tumors.	lenvatinib	49-59	CD274 molecule	Homo sapiens	95-120	
34036623-10	2021	CONCLUSIONS: Lenvatinib reduced tumor PD-L1 level and Treg differentiation to improve anti-PD-1 efficacy by blocking FGFR4.	lenvatinib	13-23	CD274 molecule	Homo sapiens	38-43	
34168004-0	2021	Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma.	lenvatinib	46-56	CD274 molecule	Homo sapiens	76-81	
34168004-3	2021	In this study, we elucidate the stimulators of PD-L1+ neutrophils in tumor microenvironment (TME) and explore the optimal combination to enhance the effect of lenvatinib by inhibiting PD-L1+ neutrophils in hepatocellular carcinoma.	lenvatinib	159-169	CD274 molecule	Homo sapiens	47-52	
34168004-3	2021	In this study, we elucidate the stimulators of PD-L1+ neutrophils in tumor microenvironment (TME) and explore the optimal combination to enhance the effect of lenvatinib by inhibiting PD-L1+ neutrophils in hepatocellular carcinoma.	lenvatinib	159-169	CD274 molecule	Homo sapiens	184-189	
34036623-3	2021	APPROACH & RESULTS: First, in patients with HCC, lenvatinib-treated recurrent tumors had lower programmed death ligand 1 (PD-L1) expression and regulatory T cell (Treg) infiltration compared with matched primary tumors.	lenvatinib	49-59	CD274 molecule	Homo sapiens	122-127	
32087304-11	2020	Knock down of HDACs1/2/3 prevented the lenvatinib and entinostat combination from regulating PD-L1 and MHCA expression.	lenvatinib	39-49	CD274 molecule	Homo sapiens	93-98	
33757737-12	2021	In patients with >=1% PD-L1 expression, the highest likelihood of better PFS was associated with lenvatinib plus pembrolizumab and nivolumab plus ipilimumab.	lenvatinib	97-107	CD274 molecule	Homo sapiens	22-27	
32647635-16	2020	Finally, lenvatinib inhibited PD-L1 expression on human umbilical vein endothelial cells, which improved the function of T cells.	lenvatinib	9-19	CD274 molecule	Homo sapiens	30-35